| abstract |
The present invention provides a delayed-release compartment comprising losaltan (2-butyl-4-chloro-1- [p- (o-1H-tetrazol-5-ylphenyl) benzyl] imidazole-5-methanol) as a pharmacologically active ingredient; Rosuvastatin (bis [(E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3R, 5S) as a pharmacologically active ingredient A pharmaceutical formulation comprising a prior release compartment comprising of -3,5-dihydroxyhept-6-enoic acid) is provided.n n n The pharmaceutical preparations of the present invention are designed to control and release the drug at a specific time and rate, so that patients with so-called metabolic syndrome, including hypertension and hyperlipidemia, prevention of complications, as well as diabetes, obesity, hyperlipidemia, coronary artery disease, etc. It is very effective in treating hypertension and hyperlipidemia and preventing complications. |